B/BE/02/B7
| Company/Institution | Transgene S.A. |
| Parental organism | Attenuated Vaccinia Virus (Ankara Strain) |
| Transgene(s) | sequences coding for the human MUC-1 antigen and IL-2 |
| Treated organism | Humans |
| Title of the project | Phase II study evaluating the clinical efficacy of TG4010(MVA-MUC-1-IL-2) in patients with metastatic renal cell carcinoma |
| Treatment indication | metastatic renal cell carcinoma |
| Administration route(s) | Subcutaneous |
| Total number of subjects foreseen | not specified (up to 32 patients in Europe) |
| Foreseen duration of release | 1 year |
| Effective year(s) of release | 2 years |
| Current status | Trial completed |
| Locations | Bruxelles: Cliniques Universitaires St Luc, Hôpital Erasme |
| Number of sites | 2 |
| Monitoring | |
| Type of procedure | Classical procedure - Art. 9§1 of Royal Decree of 18 December 1998 |
| Notes | |
| Other |
Information for the public
- B/BE/02/B7 - Public information sheet (written by the notifier)
- B/BE/02/B7 - Fiche d'information destinée au public (préparée par le notifiant)
- B/BE/02/B7 – Informatie fiche bestemd voor het publiek (voorbereid door de kennisgever)
-
B/BE/02/B7 - Summary Notification Information Format (SNIF)
Public information presented according to the provisions of Directive 2001/18/EC
Information related to the decision procedure
-
B/BE/02/B7 - Advies van de a.i. Adviesraad voor Bioveiligheid / Avis du Conseil Consultatif de Biosécurité a.i.
09 August 2002: The Biosafety Advisory Council a.i. issues a positive advice for this trial (the advice is written in French and Dutch)
-
B/BE/02/B7 – Advice of the Regional Competent Authority
18 February 2002: The Regional Competent Authority issues a positive advice
-
B/BE/02/B7 - Decision of the Federal Ministry (FINAL DECISION)
22 October 2002: The Federal Ministry for Food chain safety and Environment gives a final decision (positive) for this trial.
